...in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis... ...€5 million ($6.4 million) in milestones to develop Viaskin HDM through Phase II testing, while Genclis... ...will retain rights to IP related to its own products. DBV Technologies (Euronext:DBV), Bagneux, France Genclis S.A.S....
Separate academic teams have collaborated with Alnylam Pharmaceuticals Inc. to target small interfering RNAs to immune cells residing in the spleen. The therapeutics silence inflammatory or antigen-presenting immune cells before they migrate to tissues where...
This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Lipid nanoparticle formulations for spleen-specific delivery of small interfering RNA to macrophages and dendritic cells (DCs) Mouse studies suggest large lipid...
...in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis... ...€5 million ($6.4 million) in milestones to develop Viaskin HDM through Phase II testing, while Genclis... ...will retain rights to IP related to its own products. DBV Technologies (Euronext:DBV), Bagneux, France Genclis S.A.S....
Separate academic teams have collaborated with Alnylam Pharmaceuticals Inc. to target small interfering RNAs to immune cells residing in the spleen. The therapeutics silence inflammatory or antigen-presenting immune cells before they migrate to tissues where...
This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Lipid nanoparticle formulations for spleen-specific delivery of small interfering RNA to macrophages and dendritic cells (DCs) Mouse studies suggest large lipid...
